# Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer

> **NCT07393048** · — · RECRUITING · sponsor: **Beijing Friendship Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer (LARC)

## Interventions

- **DIAGNOSTIC_TEST:** Personalized ctDNA-MRD Detection

## Key facts

- **NCT ID:** NCT07393048
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-15
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07393048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07393048, "Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant Therapy for Rectal Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07393048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*